Open AccessClozapine‐induced myocarditis: Follow‐up for 3.5 years after successful retrial
Author(s) -
Otsuka Yuji,
Idemoto Keita,
Hosoda Yutaka,
Imamura Yukitsugu,
Aoki Tsutomu
Publication year - 2019
Publication title -
journal of general and family medicine
Language(s) - English
Resource type - Journals
ISSN - 2189-7948
DOI - 10.1002/jgf2.239
Subject(s) - clozapine , medicine , myocarditis , schizophrenia (object oriented programming) , antipsychotic , population , anesthesia , psychiatry , environmental health
Schizophrenia patients have significantly lower life expectancy than the general population. Clozapine is the most effective antipsychotic to reduce the mortality rate in these patients. Here, we report a schizophrenic patient with clozapine‐induced myocarditis and successful retrial. In the first trial, clozapine was discontinued due to myocarditis. In the second trial, the titration rate was slower, and sodium valproate was not coadministered with clozapine. The patient has not developed myocarditis over 3.5 years of observation. It may be possible to take clozapine for a long time even after clozapine‐induced myocarditis, and thus improve the life expectancy of schizophrenia patients.